Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Challenging case

  • Vanisha Seetaram
  • Vanisha Seetaram's Avatar Topic Author
3 years 4 weeks ago #1847 by Vanisha Seetaram
Challenging case was created by Vanisha Seetaram
Male 20 yrs old, was on gleevec 600mg od, wcc57.94, hb14, plts 338 2019. Same dose follow up till June 2021, wcc 4.14 n2.42 hb 13 plts 149 gleevec decreased to 200mg od. Aug 2021wcc 3.32 n 1.97 hb11.6 plts 92, continues on gleevec 200mg od. On 17.09.2021, plts 32, no gleevec was transfused with plts. 08.10.2021 wcc 36.7 n56% hb9.1 plts 58, BMA done showed CML In blast crisis, blasts 40%. Received 1 dose of cytarabine 100mg. On 22.10.2021 wcc 15.24 ig17.8 hb10.1 plts 21, was transfused with plts. Stuck with way forward for this patient. Please advise.
Quick Reply

Reply to Vanisha Seetaram

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Giuseppe Saglio
  • Giuseppe Saglio's Avatar Topic Author
3 years 4 weeks ago - 3 years 4 weeks ago #1848 by Giuseppe Saglio
Replied by Giuseppe Saglio on topic Challenging case
We do not know if this blast crisis is lymphoid or myeloid. To know this as well as to search for mutations is essential to know which chemo and which TKI has to be used in combination (certainly not imatinib). If the mutation analysis cannot be performed Ponatinib 45mg a day is the best solution, to be associated with dexamethasone (at a dose of 20 mg per day)-If there is a persistent MRD positivity (measurable) I would consider Blinatumomab to reach at least MR4 or MR4.5, but allo SCT is always needed. If the BC is myeloid I would associated the ponatinib or at least dasatinib to the AML chemocycle that you use in AML. The goal in anycase is to reach a good remission (at least MMR, but deeper is always better) and then to move the patient to an allo transplant. More details are needed. and if you want you can write me directly.

If you do not have facilities to perform this kind of therapies, as Mauritius according to my knowledge is an extra European territory of France, the best option is to move the patient to France.
Last edit: 3 years 4 weeks ago by arlene.
Quick Reply

Reply to Giuseppe Saglio

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene